WRAL Tech Wire

BioMarck Pharmaceuticals closes on $7.5 million in new financing

BioMarck

Local Tech Wire

RALEIGH, N.C. – Startup BioMarck Pharmaceuticals has wrapped up an effort to raise $7.5 million in new financing, according to a filing with the Securities and Exchange Commission.

The close comes five months after the drug research firm secured two more U.S. patents. It also was awarded a $990,000 National Institutes of Health grant in February.

One new patent covers its lead compound which targets mucus in respiratory diseases. The second covers anti-inflammatory research.

BioMarck’s work forces on peptides. The patents will cover treatment of pulmonary diseases related to mucus and airway inflammation, the company said. It also is seeking international patent coverage.

The lung treatment drug, which is undergoing clinical trial, is designed to combat mucus. According to BioMarck, there are no drugs that treat pulmonary disease by targeting the excessive mucus secretion.

BioMarck licensed its technology from N.C. State,

In 2007, BioMarck secured $4 million in venture funding and won U.S. patent coverage for other key parts of its technology.

Kenneth Adler, a professor of cell biology at NCSU, made the discoveries that led to the development of BioMarck’s technology.
 

Please log in to view WRALTechWire Insider content

To access this premium content and other benefits, become a WRAL TechWire Insider. Daily, monthly, and annual memberships available.

Editor's Blog

The latest blog posts from our WRAL Tech Wire and WRAL editors. Read more articles…